Alkermes Plc. ALKS
We take great care to ensure that the data presented and summarized in this overview for Alkermes plc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ALKS
View all-
Black Rock Inc. New York, NY29.2MShares$704 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA20.2MShares$487 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA14.9MShares$360 Million0.07% of portfolio
-
State Street Corp Boston, MA9MShares$217 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD8.33MShares$201 Million0.03% of portfolio
-
Rtw Investments, LP New York, NY6.05MShares$146 Million2.63% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny5.89MShares$142 Million0.25% of portfolio
-
Pictet Asset Management Sa Geneva 73, V84.79MShares$116 Million0.18% of portfolio
-
Pacer Advisors, Inc. Malvern, PA4.28MShares$103 Million0.3% of portfolio
-
Geode Capital Management, LLC Boston, MA3.74MShares$90.4 Million0.01% of portfolio
Latest Institutional Activity in ALKS
Top Purchases
Top Sells
About ALKS
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Insider Transactions at ALKS
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Mar 18
2024
|
Christian Todd Nichols SVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
10,417
-13.65%
|
$291,676
$28.1 P/Share
|
Feb 27
2024
|
Samuel Joseph Parisi VP, Finance (Interim PAO) |
SELL
Open market or private sale
|
Direct |
2,559
-24.9%
|
$74,211
$29.65 P/Share
|
Feb 23
2024
|
Christian Todd Nichols SVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,845
-3.59%
|
$82,505
$29.57 P/Share
|
Feb 23
2024
|
Christian Todd Nichols SVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,407
+7.49%
|
-
|
Feb 23
2024
|
Iain Michael Brown SVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,587
-2.18%
|
$75,023
$29.57 P/Share
|
Feb 23
2024
|
Iain Michael Brown SVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,825
+4.67%
|
-
|
Feb 23
2024
|
Samuel Joseph Parisi VP, Finance (Interim PAO) |
SELL
Payment of exercise price or tax liability
|
Direct |
672
-6.14%
|
$19,488
$29.57 P/Share
|
Feb 23
2024
|
Samuel Joseph Parisi VP, Finance (Interim PAO) |
BUY
Exercise of conversion of derivative security
|
Direct |
2,283
+17.25%
|
-
|
Feb 23
2024
|
Blair Curtis Jackson EVP, Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,880
-2.4%
|
$112,520
$29.57 P/Share
|
Feb 23
2024
|
Blair Curtis Jackson EVP, Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,737
+5.13%
|
-
|
Feb 23
2024
|
Michael J Landine SVP, Corp Dev., Alkermes, Inc. |
SELL
Payment of exercise price or tax liability
|
Direct |
1,811
-0.64%
|
$52,519
$29.57 P/Share
|
Feb 23
2024
|
Michael J Landine SVP, Corp Dev., Alkermes, Inc. |
BUY
Exercise of conversion of derivative security
|
Direct |
4,077
+1.42%
|
-
|
Feb 23
2024
|
David Joseph Gaffin EVP, CLO, Alkermes, Inc. |
SELL
Payment of exercise price or tax liability
|
Direct |
3,414
-2.03%
|
$99,006
$29.57 P/Share
|
Feb 23
2024
|
David Joseph Gaffin EVP, CLO, Alkermes, Inc. |
BUY
Exercise of conversion of derivative security
|
Direct |
7,689
+4.37%
|
-
|
Feb 23
2024
|
Craig C. Hopkinson EVP R&D, Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,414
-3.02%
|
$99,006
$29.57 P/Share
|
Feb 23
2024
|
Craig C. Hopkinson EVP R&D, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,689
+6.36%
|
-
|
Feb 22
2024
|
Christian Todd Nichols SVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,156
-4.16%
|
$88,368
$28.91 P/Share
|
Feb 22
2024
|
Christian Todd Nichols SVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,108
+8.56%
|
-
|
Feb 22
2024
|
Samuel Joseph Parisi VP, Finance (Interim PAO) |
SELL
Payment of exercise price or tax liability
|
Direct |
908
-9.49%
|
$25,424
$28.91 P/Share
|
Feb 22
2024
|
Samuel Joseph Parisi VP, Finance (Interim PAO) |
BUY
Exercise of conversion of derivative security
|
Direct |
3,114
+24.54%
|
-
|
Last 12 Months Summary
Exercise of conversion of derivative security | 331K shares |
---|---|
Grant, award, or other acquisition | 406K shares |
Payment of exercise price or tax liability | 241K shares |
---|---|
Open market or private sale | 89.5K shares |